MA37500B1 - Formulation parentérale d'esmolol - Google Patents
Formulation parentérale d'esmololInfo
- Publication number
- MA37500B1 MA37500B1 MA37500A MA37500A MA37500B1 MA 37500 B1 MA37500 B1 MA 37500B1 MA 37500 A MA37500 A MA 37500A MA 37500 A MA37500 A MA 37500A MA 37500 B1 MA37500 B1 MA 37500B1
- Authority
- MA
- Morocco
- Prior art keywords
- esmolol hydrochloride
- ready
- parenteral formulation
- pure
- solvent
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 title 1
- 229960003745 esmolol Drugs 0.000 title 1
- VZTMYLWJKCAXMZ-UHFFFAOYSA-N 2-[(2-chloroquinazolin-4-yl)amino]ethanol Chemical compound C1=CC=C2C(NCCO)=NC(Cl)=NC2=C1 VZTMYLWJKCAXMZ-UHFFFAOYSA-N 0.000 abstract 7
- 229960001015 esmolol hydrochloride Drugs 0.000 abstract 7
- 239000000843 powder Substances 0.000 abstract 3
- 239000002904 solvent Substances 0.000 abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 239000000243 solution Substances 0.000 abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 1
- 208000001871 Tachycardia Diseases 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000006794 tachycardia Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- 239000008215 water for injection Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne une formulation parentérale de chlorhydrate d'esmolol pour son utilisation dans le traitement d'un patient souffrant de tachycardie qui comprend une poudre lyophilisée constituée de chlorhydrate d'esmolol pur, ladite poudre étant reconstituée pour obtenir une solution i.V. Prête à l'emploi de chlorhydrate d'esmolol à une concentration de 20 à 100 mg/ml, et ladite solution i.V. Est directement administrée au patient. La présente invention concerne également un procédé de production d'une solution i.V. Prête à l'emploi de chlorhydrate d'esmolol par reconstitution d'une poudre constituée de chlorhydrate d'esmolol pur avec un solvant, caractérisé en ce que ledit solvant est un solvant i.V. Dépourvu d'alcool ou d'excipient tampon, en une quantité nécessaire pour obtenir une solution i.V. Prête à l'emploi à une concentration de 20 à 100 mg/ml. La présente invention concerne en outre la solution i.V. Prête à l'emploi contenant une formulation parentérale de 20 à 100 mg/ml de chlorhydrate d'esmolol pur dans un dispositif de perfusion ou consistant en une formulation parentérale de 20 à 100 mg/ml de chlorhydrate d'esmolol pur, d'eau pour injection et/ou de solution saline, et dépourvue de tout alcool ou excipient tampon.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12167443 | 2012-05-10 | ||
| PCT/EP2013/059594 WO2013167657A1 (fr) | 2012-05-10 | 2013-05-08 | Formulation parentérale d'esmolol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA37500A1 MA37500A1 (fr) | 2016-03-31 |
| MA37500B1 true MA37500B1 (fr) | 2016-12-30 |
Family
ID=48407551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37500A MA37500B1 (fr) | 2012-05-10 | 2014-11-05 | Formulation parentérale d'esmolol |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US20150087704A1 (fr) |
| EP (1) | EP2846776B1 (fr) |
| JP (1) | JP6220383B2 (fr) |
| CN (1) | CN104379134A (fr) |
| AU (1) | AU2013258031B2 (fr) |
| BR (1) | BR112014027870B1 (fr) |
| CA (1) | CA2872953C (fr) |
| CL (1) | CL2014003028A1 (fr) |
| DK (1) | DK2846776T3 (fr) |
| EA (1) | EA032344B1 (fr) |
| ES (1) | ES2794093T3 (fr) |
| HR (1) | HRP20200897T1 (fr) |
| HU (1) | HUE049314T2 (fr) |
| IL (1) | IL235497A0 (fr) |
| LT (1) | LT2846776T (fr) |
| MA (1) | MA37500B1 (fr) |
| MX (1) | MX374771B (fr) |
| MY (1) | MY173900A (fr) |
| NZ (1) | NZ701429A (fr) |
| PH (1) | PH12014502494B1 (fr) |
| PL (1) | PL2846776T3 (fr) |
| PT (1) | PT2846776T (fr) |
| SI (1) | SI2846776T1 (fr) |
| TN (1) | TN2014000464A1 (fr) |
| UA (1) | UA115333C2 (fr) |
| WO (1) | WO2013167657A1 (fr) |
| ZA (1) | ZA201408149B (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019122157A1 (fr) * | 2017-12-21 | 2019-06-27 | Ipsol Ag | Lyophilisat comprenant de l'esmolol et de l'adénosine pour une utilisation en cardioplégie |
| CN111848420A (zh) * | 2020-07-22 | 2020-10-30 | 杭州煌森生物科技有限公司 | 一种盐酸艾司洛尔的新晶型及制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6310094B1 (en) * | 2001-01-12 | 2001-10-30 | Baxter International Inc. | Ready-to-use esmolol solution |
| TWI277414B (en) | 2001-01-12 | 2007-04-01 | Baxter Int | Esmolol formulation |
| SE0401842D0 (sv) * | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| KR20080039954A (ko) * | 2005-08-31 | 2008-05-07 | 오노 야꾸힝 고교 가부시키가이샤 | 점적용 주사제 |
| US20080293814A1 (en) * | 2007-05-22 | 2008-11-27 | Deepak Tiwari | Concentrate esmolol |
| ES2397126T3 (es) | 2007-12-21 | 2013-03-04 | Aop Orphan Pharmaceuticals Ag | Composición farmacéutica para la administración parenteral de un antagonista del receptor beta-adrenérgico de acción ultrarrápida |
| CN102106846A (zh) * | 2009-12-23 | 2011-06-29 | 南京海辰药业有限公司 | 左旋盐酸艾司洛尔药物组合物及其制备方法 |
-
2013
- 2013-05-08 ES ES13721740T patent/ES2794093T3/es active Active
- 2013-05-08 JP JP2015510815A patent/JP6220383B2/ja active Active
- 2013-05-08 PL PL13721740T patent/PL2846776T3/pl unknown
- 2013-05-08 AU AU2013258031A patent/AU2013258031B2/en active Active
- 2013-05-08 WO PCT/EP2013/059594 patent/WO2013167657A1/fr not_active Ceased
- 2013-05-08 CA CA2872953A patent/CA2872953C/fr active Active
- 2013-05-08 UA UAA201413014A patent/UA115333C2/uk unknown
- 2013-05-08 NZ NZ701429A patent/NZ701429A/en unknown
- 2013-05-08 CN CN201380028099.XA patent/CN104379134A/zh active Pending
- 2013-05-08 HU HUE13721740A patent/HUE049314T2/hu unknown
- 2013-05-08 PT PT137217402T patent/PT2846776T/pt unknown
- 2013-05-08 BR BR112014027870-9A patent/BR112014027870B1/pt active IP Right Grant
- 2013-05-08 SI SI201331732T patent/SI2846776T1/sl unknown
- 2013-05-08 MY MYPI2014703249A patent/MY173900A/en unknown
- 2013-05-08 HR HRP20200897TT patent/HRP20200897T1/hr unknown
- 2013-05-08 MX MX2014013556A patent/MX374771B/es active IP Right Grant
- 2013-05-08 EP EP13721740.2A patent/EP2846776B1/fr active Active
- 2013-05-08 EA EA201491841A patent/EA032344B1/ru not_active IP Right Cessation
- 2013-05-08 US US14/398,312 patent/US20150087704A1/en not_active Abandoned
- 2013-05-08 LT LTEP13721740.2T patent/LT2846776T/lt unknown
- 2013-05-08 DK DK13721740.2T patent/DK2846776T3/da active
-
2014
- 2014-10-31 TN TN2014000464A patent/TN2014000464A1/fr unknown
- 2014-11-04 IL IL235497A patent/IL235497A0/en active IP Right Grant
- 2014-11-05 MA MA37500A patent/MA37500B1/fr unknown
- 2014-11-07 ZA ZA2014/08149A patent/ZA201408149B/en unknown
- 2014-11-07 PH PH12014502494A patent/PH12014502494B1/en unknown
- 2014-11-07 CL CL2014003028A patent/CL2014003028A1/es unknown
-
2017
- 2017-07-28 US US15/663,645 patent/US20170326095A1/en not_active Abandoned
-
2022
- 2022-01-24 US US17/582,945 patent/US11963940B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009106862A (ru) | Способы и композиции, повышающие переносимость пациентом методов визуализации миокарда | |
| EA201270167A1 (ru) | Лекарственная форма глатирамера ацетата с уменьшенным объемом и способы введения | |
| JP2017519018A5 (fr) | ||
| MX389346B (es) | Formulaciones de anticuerpos monoclonales de alta concentración. | |
| HRP20200072T1 (hr) | Načini doziranja za spojeve klase ehinokandina | |
| FI3581199T3 (fi) | Menetelmiä turvottavan fibroskleroottisen pannikulopatian hoitamiseksi tai vähentämiseksi | |
| EA201691790A1 (ru) | Способ получения продукта глатирамера ацетата | |
| EP2358395A4 (fr) | Procédé et formulation pour réduire l'agrégation d'une macromolécule dans des conditions physiologiques | |
| AR084816A1 (es) | Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer | |
| RU2015116264A (ru) | Композиции и способы лечения сердечной недостаточности у пациентов с диабетом | |
| FI3383385T4 (fi) | Melflufeeniannoskuureja syöpään | |
| PH12015501373A1 (en) | Injectable depot formulation comprising optically active tolvaptan and process of producing the same | |
| EA201691055A1 (ru) | Препараты и способы лечения gd2-положительного рака | |
| MA37500A1 (fr) | Formulation parentérale d'esmolol | |
| PE20130782A1 (es) | Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo | |
| MA40599A1 (fr) | Formulations injectables de paracétamol | |
| MY174442A (en) | Treating critically ill patients with intravenous ibuprofen | |
| EA032959B1 (ru) | Применение бремеланотида в терапии женской сексуальной дисфункции | |
| RU2011101481A (ru) | Способ профилактики острой декомпрессионной болезни | |
| RU2010133699A (ru) | Способ комбинированного лечения глаукомной оптической нейропатии | |
| RU2013148539A (ru) | Алиспоривир для лечения инфекции вируса гепатита с | |
| RU2023131642A (ru) | Применение долгодействующих пептидов glp-1 | |
| RU2021110820A (ru) | Композиции и способы для повышения способности к системной доставке, переносимости и эффективности катионных макроциклических пептидов | |
| Kadowaki et al. | EFFECT OF ACETAMINOPHEN ON PROGRESSION OF RENAL DAMAGE IN ADENINEINDUCED RENAL FAILURE MODEL RAT | |
| MA37811A1 (fr) | Solution d'acétaminophène injectable sursaturée pour l'administration spinale |